首页|中西医结合治疗非酒精性脂肪肝疗效的Meta分析

中西医结合治疗非酒精性脂肪肝疗效的Meta分析

扫码查看
目的:系统评价中西药结合治疗非酒精性脂肪肝的疗效,为临床合理应用提供证据.方法:时间限定为2018 年1月1日-2022 年1月1日,通过对检索PubMed、Cochrane Library、Embase、万方数据库、中国知网、维普数据库、中国生物医学文献数据库,选择了中西医结合治疗非酒精性脂肪肝的文献,提取了治疗非酒精性脂肪肝的随机对照试验.选择符合标准的进行质量评估,并使用RevMan 5.3 软件进行荟萃分析处理,计数资料用相对危险度(RR)为效应量,计量资料用均值差(MD)或标准均值差(SMD)表示效应量,各效应量均计算95%可信区间(CI).I2 统计量和P值用来评估纳入文献异质性,若P>0.05,I2≤50%,采用固定效应进行分析,否则使用随机效应进行Meta分析.结果:共检索到 363篇,最终纳入 34篇文献,共涉及 2 973 例患者,其中中西医结合治疗组 1 489 例,纯西医治疗组 1 484 例.与纯西医治疗组相比,中西医结合治疗组显示出更高的总疗效[RR=1.23,95%CI(1.19,1.27),P<0.000 01]、谷丙转氨酶[MD =-13.17,95%CI(-15.25,-11.05),P<0.000 01]、谷草转氨酶[MD=-11.22,95%CI(-12.80,-9.64),P<0.000 01]、三酰甘油[MD=-0.72,95%CI(-0.86,-0.58),P<0.000 01]、总胆固醇[MD =-0.96,95%CI(-1.13,-0.80),P<0.000 01],差异有统计学意义,而身体质量指数[MD =-3.13,95%CI(-8.06,-1.81),P= 0.21]差异无统计学意义.结论:在非酒精性肝病的治疗中,西药和中药的组合优于单独的西药,可以显著改善非酒精性肝病脂质代谢,提高临床疗效,并且有明确的安全性,但需要质量更好的随机对照试验来证实这一点.
A Meta-analysis of the efficacy of integrative medicine on non-alcoholic fatty liver disease
Objective:To systematically evaluate the efficacy of integrative medicine on non-alcoholic fatty liver disease,and provide evidence for rational clinical application.Methods:The time was limited to January 1,2018 to January 1,2022.By searching PubMed,Cochrane Library,Embase,Wanfang Database,CNKI,VIP database and CBM database,we selected the literature on the treatment of non-alcoholic fatty liver with integrative medicine,and extracted the RCTs for the treatment of non-alcoholic fatty liver.RCTs that meet the criteria were selected for quality evaluation,and Meta-analysis was carried out using RevMan 5.3 software.RR was used as the effect amount for counting data,MD or SMD was used for measurement data,and 95%CI was calculated for each effect amount.The I2 statistic and P value were used to assess the heterogeneity of the included literature,and if P>0.05 and I2≤50%,fixed effects were used for analysis,otherwise random effects were used for Meta-analysis.Results:A total of 363 articles were retrieved,and 34 articles were finally included,involving a total of 2 973 patients.There were 1 489 cases in the experimental group and 1 484 cases in the control group.Compared with the control group,the experimental group showed higher total efficiency[RR=1.23,95%CI(1.19,1.27),P<0.000 01],ALT[MD=-13.17,95%CI(-15.25,-11.05),P<0.000 01],AST[MD=-11.22,95%CI(-12.80,-9.64),P<0.000 01],TG[MD=-0.72,95%CI(-0.86,-0.58),P<0.000 01],and TC[MD=-0.96,95%CI(-1.13,-0.80),P<0.000 01],and the difference was statistically significant.While the differences in BMI[MD=-3.13,95%CI(-8.06,-1.81),P=0.21],the difference was not statistically significant.Conclusion:In the treatment of non-alcoholic fatty liver disease,the integrative medicines is superior to western medicines alone and can significantly improve lipid metabolism in non-alcoholic fatty liver disease,improve clinical efficacy and have a clear safety profile,but better quality RTCs are needed to confirm this.

The integrative medicineNon-alcoholic fatty liver diseaseRandomized controlled trialMeta-analysis

沈宇煌、龚先琼

展开 >

福建中医药大学第二临床医学院,福建 福州,350122

福建中医药大学附属厦门中医院,福建 厦门,361009

中西医结合治疗 非酒精性脂肪肝 随机对照 Meta分析

厦门市重大疾病防治科技惠民项目福建省卫生健康中青年骨干人才培养项目

3502Z202310322022GGB020

2024

中医临床研究
中华中医药学会

中医临床研究

影响因子:0.839
ISSN:1674-7860
年,卷(期):2024.16(2)
  • 41